EG24127A - Process for 5-((2(R)-(1(R)(3,5 Bis (Trifluoromethyl)phenyl)ethoxy)-3(S)-(4-Fluorophenyl)-4-Morpholinyl)methyl)-1,2-Dihydro-3H-1,2,4-triazol-3-one - Google Patents

Process for 5-((2(R)-(1(R)(3,5 Bis (Trifluoromethyl)phenyl)ethoxy)-3(S)-(4-Fluorophenyl)-4-Morpholinyl)methyl)-1,2-Dihydro-3H-1,2,4-triazol-3-one

Info

Publication number
EG24127A
EG24127A EG2003040353A EG2003040353A EG24127A EG 24127 A EG24127 A EG 24127A EG 2003040353 A EG2003040353 A EG 2003040353A EG 2003040353 A EG2003040353 A EG 2003040353A EG 24127 A EG24127 A EG 24127A
Authority
EG
Egypt
Prior art keywords
triazol
morpholinyl
fluorophenyl
dihydro
trifluoromethyl
Prior art date
Application number
EG2003040353A
Other languages
English (en)
Inventor
Mark Huffman
Original Assignee
Merck & Co Inc
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Merck Sharp & Dohme filed Critical Merck & Co Inc
Application granted granted Critical
Publication of EG24127A publication Critical patent/EG24127A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EG2003040353A 2002-04-18 2003-04-19 Process for 5-((2(R)-(1(R)(3,5 Bis (Trifluoromethyl)phenyl)ethoxy)-3(S)-(4-Fluorophenyl)-4-Morpholinyl)methyl)-1,2-Dihydro-3H-1,2,4-triazol-3-one EG24127A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37373402P 2002-04-18 2002-04-18

Publications (1)

Publication Number Publication Date
EG24127A true EG24127A (en) 2008-07-08

Family

ID=29251070

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2003040353A EG24127A (en) 2002-04-18 2003-04-19 Process for 5-((2(R)-(1(R)(3,5 Bis (Trifluoromethyl)phenyl)ethoxy)-3(S)-(4-Fluorophenyl)-4-Morpholinyl)methyl)-1,2-Dihydro-3H-1,2,4-triazol-3-one

Country Status (21)

Country Link
US (1) US7847095B2 (pt)
EP (1) EP1499611B1 (pt)
JP (1) JP4271586B2 (pt)
KR (1) KR100982901B1 (pt)
CN (1) CN1293077C (pt)
AR (1) AR039625A1 (pt)
AU (1) AU2003228578B2 (pt)
BR (1) BR0309277A (pt)
CA (1) CA2482466C (pt)
EG (1) EG24127A (pt)
HR (1) HRP20040974A2 (pt)
IL (1) IL164586A (pt)
MX (1) MXPA04010182A (pt)
NO (1) NO330362B1 (pt)
NZ (1) NZ535883A (pt)
PL (1) PL217076B1 (pt)
RU (1) RU2326879C2 (pt)
TW (1) TWI341313B (pt)
UA (1) UA84399C2 (pt)
WO (1) WO2003089429A1 (pt)
ZA (1) ZA200408193B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
EP1934204A2 (en) 2005-10-05 2008-06-25 Ranbaxy Laboratories, Ltd. Process for preparation of aprepitant
US8133994B2 (en) 2005-10-06 2012-03-13 Dr. Reddy's Laboratories Ltd. Preparation of aprepitant
EP1984359A1 (en) * 2006-02-03 2008-10-29 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
US20090149462A1 (en) * 2006-08-28 2009-06-11 Hetero Drugs Limited Process for purification of aprepitant
CN102295611B (zh) * 2010-05-24 2014-09-10 成都地奥制药集团有限公司 一种神经激肽1受体拮抗剂类药物的合成方法
HUP1000325A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
WO2012146692A1 (en) 2011-04-29 2012-11-01 Sandoz Ag Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
CN103030668B (zh) * 2011-10-09 2016-06-15 江苏豪森药业集团有限公司 一种制备福沙匹坦二甲葡胺的方法
PT2817305T (pt) * 2012-02-23 2016-11-02 Piramal Entpr Ltd Um processo melhorado para a preparação de aprepitant
CZ304770B6 (cs) 2012-03-13 2014-10-08 Zentiva, K.S. Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II
ITMI20130273A1 (it) * 2013-02-26 2014-08-27 Olon Spa Procedimento per la preparazione di aprepitant
CN103288813A (zh) * 2013-06-04 2013-09-11 四川百利药业有限责任公司 一种阿瑞匹坦的制备方法
CN107954998B (zh) * 2016-10-14 2022-08-12 江苏豪森药业集团有限公司 福沙匹坦中间体的制备方法
CN106967057A (zh) * 2017-06-01 2017-07-21 四川制药制剂有限公司 一种阿瑞匹坦高效制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637699A (en) 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
GB9813025D0 (en) 1998-06-16 1998-08-12 Merck Sharp & Dohme Chemical synthesis

Also Published As

Publication number Publication date
CA2482466A1 (en) 2003-10-30
CN1293077C (zh) 2007-01-03
JP4271586B2 (ja) 2009-06-03
KR20050007299A (ko) 2005-01-17
IL164586A (en) 2010-11-30
PL373348A1 (en) 2005-08-22
EP1499611A1 (en) 2005-01-26
TWI341313B (en) 2011-05-01
MXPA04010182A (es) 2005-02-03
BR0309277A (pt) 2005-02-22
WO2003089429A1 (en) 2003-10-30
AU2003228578B2 (en) 2009-07-30
US20050215786A1 (en) 2005-09-29
NO330362B1 (no) 2011-04-04
TW200400189A (en) 2004-01-01
UA84399C2 (en) 2008-10-27
US7847095B2 (en) 2010-12-07
CN1646525A (zh) 2005-07-27
NZ535883A (en) 2007-12-21
HRP20040974A2 (en) 2005-06-30
AU2003228578A1 (en) 2003-11-03
CA2482466C (en) 2012-11-20
RU2326879C2 (ru) 2008-06-20
NO20045001L (no) 2004-11-17
ZA200408193B (en) 2006-06-28
EP1499611B1 (en) 2015-02-11
RU2004133678A (ru) 2005-05-27
IL164586A0 (en) 2005-12-18
JP2005529881A (ja) 2005-10-06
PL217076B1 (pl) 2014-06-30
EP1499611A4 (en) 2006-05-03
KR100982901B1 (ko) 2010-09-20
AR039625A1 (es) 2005-03-02

Similar Documents

Publication Publication Date Title
EG24127A (en) Process for 5-((2(R)-(1(R)(3,5 Bis (Trifluoromethyl)phenyl)ethoxy)-3(S)-(4-Fluorophenyl)-4-Morpholinyl)methyl)-1,2-Dihydro-3H-1,2,4-triazol-3-one
PL371527A1 (en) Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterial, related compositions and methods
ATE529162T1 (de) Verfahren zur herstellung von (3-(2(r)-((1r)-1-(3,5-bis(trifluoromethyl)pheny )ethoxy)-3(s)-(4- fluorophenyl)morpholin-4-yl)methyl)-5-oxo-4,5- dihydro-(1,2,4)-triazol-1-yl)-phosphonsäure
ZA200207372B (en) Method for implementing scheduled return play at gaming machine networks.
HK1090294A1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4- oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate ;
PL359137A1 (en) Process for the synthesis of (2r, 2-alpha-r, 3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine
AU2001236606A1 (en) 3,4-dihydro-2h-benzo(1,4)oxazine inhibitors of factor xa
DE69602970D1 (de) 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol-2(3h)-on-derivate verwendbar als 5-ht4- oder h3-rezeptorliganden
ZA200700159B (en) Phenyl substituted [1.2]-oxazine-3,5-dione and dihydropyrone derivatives
ITRM20010071A0 (it) Blocco sganciabile per una fondina a cappuccio rotante.
MXPA03008216A (es) Derivados de 3-fenilo.
AU2001266690A1 (en) Process for the synthesis of (2r, 2-alpha-r)-4-benzyl-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-1,4-oxazin-3-one
AU2001269749A1 (en) Trans-glycosidation process for the synthesis of (2r, 2-alpha-r, 3a)-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-3-(4-fluorophenyl)-1,4-oxazine
MXPA03006958A (es) Composicion para administracion rectal de farmaco antibacterial de oxazolidinona.
IL151566A0 (en) Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
AU2001271418A1 (en) 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds
AU2001268290A1 (en) Intramolecular glycosidation process for the synthesis of (2r, 2-alpha-r, 3a)-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-3-(4-fluorophenyl)-1,4-oxazine
EP0908454A3 (en) Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents
HUP0303969A3 (en) Method for producing 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane
AU2003222435A1 (en) Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
PT1123281E (pt) Compostos 3-(fenil substituido)-5-(ciclopropil substituido)1,2,4-triazole
AU2003259866A8 (en) Process for preparing 3-chloromethyl-1,2,4-triazolin-5-one
AU2002238645A1 (en) Method for preparing compounds derived from thiazolidinedione, oxazolidinedione
GB2385051B (en) Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
IL164377A (en) Methods of preparation of 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone